此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

膳食硝酸盐和性别对 COVID-19 疫苗诱导的健康男性和女性血管功能障碍的影响的调查 (DiNOVasc-COVID-19)

2026年9月22日 更新者:Queen Mary University of London

一项双盲、随机、安慰剂对照的平行研究,旨在研究膳食硝酸盐和性别对 COVID-19 疫苗诱发的健康男性和女性血管功能障碍的影响

Inorganic nitrate can protect blood vessels from the damage that occurs during cardiovascular disease. Early experimental work suggests that nitrate-induced improvements in vascular function relate to the suppression of inflammatory pathways. Whether this protection against inflammation-induced damage to the blood vessel wall might also be functional in the setting of COVID-19 vaccination will be investigated.

Vascular function will be assessed before and after the healthy participant has received their COVID-19-vaccination. Whether there might be differences in the response to the vaccine between the sexes and whether a dietary nitrate intervention impacts upon the effects of vaccination will be investigated.

The study is in two parts:

Part A: To assess sex differences in the vascular response to COVID-19 vaccination.

Part B: To assess whether inorganic nitrate, in the form of dietary inorganic nitrate supplementation compared to placebo control, can raise circulating plasma nitrite levels and thereby prevent the systemic inflammation that causes vascular dysfunction.

研究概览

详细说明

Whether the COVID-19 vaccine can be used to study endothelial dysfunction and whether inorganic nitrate might be useful in restoring the function of the endothelium in a scenario simulating the COVID-19 infection setting will be investigated.

Furthermore, sex differences in the vascular response to the COVID-19 vaccination will be investigated.

Design: A prospective randomised, double-blind, placebo-controlled trial.

Target population: A total of 98 healthy participants will be recruited. Part A: 30 participants (15 male, 15 female.) Part B: 68 participants (34 intervention, 34 placebo). Participants will be recruited prior to receiving the COVID-19 vaccination, via Barts Health NHS Trust approved vaccination hubs.

Setting: Equal numbers of healthy male and female volunteers, aged between 18 and 60 years of age, will be recruited. Following recruitment, participants will undergo baseline measurements of vascular function of flow mediated dilatation (FMD) and pulse wave analysis/velocity (PWA, PWV), in addition to haematological and clinical biochemical analyses. Volunteers will then be randomised into one of the 2 study Parts (Part A: sex differences in vascular response to COVID-19 vaccine, Part B: influence of dietary nitrate upon vascular responses to COVID-19 vaccine). If randomised to Part B, volunteers will be treated with 3 days of either 4-5mmol nitrate-containing beetroot juice or placebo. If randomised to Part A, the volunteers will not receive an intervention. On day 3, all participants will receive their COVID-19 vaccine. At 8±2hours after the vaccine, the participants will undergo repeat measurements of vascular function. A quality of life questionnaire will be obtained 28 days after the vaccine has been administered.

Intervention: All volunteers will receive COVID-19 vaccination in Part A and Part B. In Part B of the study, volunteers will be randomised in a 1:1 fashion to receive either nitrate-containing beetroot juice (4-5mmol nitrate) or nitrate-deplete placebo.

The study will take place in the Clinical Research Centre at The William Harvey Research Institute.

Analysis: For the analysis of Part A linear regression will be used to compare change in vascular dysfunction from pre- to post-vaccination between the sexes, unadjusted and adjusted for important risk factors including age, BMI and baseline vessel diameter. For Part B analysis of covariance (ANCOVA) will be used to compare change in vascular dysfunction from pre- to post-vaccination between dietary nitrate and placebo control groups adjusting for pre-vaccination level, and to compare change in plasma nitrite between dietary nitrate and placebo control groups adjusting for baseline nitrite level.

研究类型

介入性

注册 (实际的)

42

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • London、英国、EC1M 6BQ
        • The William Harvey Research Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Healthy volunteers with a booking for COVID-19 vaccination slot as per government guidelines
  2. Aged 18-60
  3. Volunteers who are willing to sign the consent form

Exclusion Criteria:

  1. Aged <18 or >60 years
  2. Healthy subjects unwilling to consent
  3. Pregnant, or any possibility that a subject may be pregnant
  4. History of any serious illnesses, including recent infections or trauma
  5. Subjects taking systemic medication (other than the oral contraceptive pill)
  6. Subjects with self-reported use of mouthwash or tongue scrapes
  7. Subjects with recent (2 weeks) or current antibiotic use
  8. Subjects with a history, or recent treatment of (within last 3 months) any oral condition (excluding caries), including gingivitis, periodontitis and halitosis
  9. Subjects with a history of COVID-19 vaccination
  10. Subjects with any history of a blood-borne infectious

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:A部分:男性健康志愿者

COVID-19 vaccine as offered by NHS England

实验性的:A部分:女性健康志愿者

COVID-19 vaccine as offered by NHS England

有源比较器:Part B: Nitrate-rich beetroot juice

Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate

COVID-19 vaccine as offered by NHS England

Beetroot juice containing approximately 5mmol/l nitrate

安慰剂比较:Part B: Nitrate-deplete beetroot juice

Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted

COVID-19 vaccine as offered by NHS England

Beetroot juice with nitrate removed

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Comparison of change in FMD from baseline between the sexes after COVID-19 vaccination
大体时间:Up to 28 days

A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between the sexes (i.e. males vs females) in Part A.

Up to 28 days
Comparison of change in FMD from baseline after COVID-19 vaccination following inorganic nitrate versus placebo supplementation
大体时间:Up to 28 days

A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between intervention and placebo in Part B.

Up to 28 days
Comparison of change in plasma [NO2-] following inorganic nitrate versus placebo supplementation
大体时间:Up to 28 days

Quantification of [NO2-] will be made using ozone chemiluminescence. Samples of blood, urine and saliva will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Measurement of [NO2-] will be made in all matrices at both timepoints, and a comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days

次要结果测量

结果测量
措施说明
大体时间
Comparison between the sexes in the systemic inflammatory response to COVID-19 vaccination
大体时间:Up to 28 days

Comparisons of the inflammatory response will be made using a combination of clinical haematology and chemistry to assess leukocyte sub-types, and inflammatory markers such as C-reactive protein. Samples of blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to inflammatory cell activation state
大体时间:Up to 28 days

Comparisons of the inflammatory cell activation state will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to circulating inflammatory mediators
大体时间:Up to 28 days

Comparisons of the inflammatory mediators will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to platelet function during systemic inflammation
大体时间:Up to 28 days

Comparisons of the platelet function will be made through the use of a platelet aggregometer and flow cytometry. Samples of citrate containing whole blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to endothelium independent vasodilation of the brachial artery
大体时间:Up to 28 days

Comparisons of endothelium independent vascular function will be made through the use brachial artery ultrasound and sublingual glyceryl trinitrate. Vascular ultrasound will be conducted at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月10日

初级完成 (实际的)

2025年12月2日

研究完成 (实际的)

2025年12月2日

研究注册日期

首次提交

2021年5月6日

首先提交符合 QC 标准的

2021年5月14日

首次发布 (实际的)

2021年5月17日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅